Technical Analysis for SPHS - Sophiris Bio

Grade Last Price % Change Price Change
grade F 0.0092 0.00% 0.0000
SPHS closed unchanged on Wednesday, August 12, 2020, on 5 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical SPHS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Older signals for SPHS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Medicine Medical Specialties RTT Clinical Medicine Biopharmaceutical Diseases Prostate Cancer Benign Prostatic Hyperplasia Men's Health Urology Bph Prostatitis Urological Diseases Andrology Johns Hopkins University Prostate The Johns Hopkins University

Is SPHS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.36
52 Week Low 0.0035
Average Volume 289,787
200-Day Moving Average 0.0000
50-Day Moving Average 0.0103
20-Day Moving Average 0.0100
10-Day Moving Average 0.0102
Average True Range 0.0043
ADX 24.48
+DI 10.5960
-DI 13.5762
Chandelier Exit (Long, 3 ATRs ) 0.0001
Chandelier Exit (Short, 3 ATRs ) 0.0189
Upper Bollinger Band 0.0122
Lower Bollinger Band 0.0078
Percent B (%b) 0.32
BandWidth 44.0000
MACD Line -0.0023
MACD Signal Line -0.0033
MACD Histogram 0.001
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0157
Resistance 3 (R3) 0.0158 0.0139 0.0146
Resistance 2 (R2) 0.0139 0.0122 0.0138 0.0142
Resistance 1 (R1) 0.0115 0.0112 0.0106 0.0114 0.0139
Pivot Point 0.0096 0.0096 0.0091 0.0095 0.0096
Support 1 (S1) 0.0072 0.0079 0.0063 0.0071 0.0045
Support 2 (S2) 0.0053 0.0069 0.0052 0.0042
Support 3 (S3) 0.0029 0.0053 0.0038
Support 4 (S4) 0.0028